1. A method of organizing advertisements in a digital home communication terminal, the method comprising:
displaying a plurality of advertisement categories corresponding to products, services, or combinations thereof;
receiving a user selection of one or more advertisement categories;
presenting an advertisement corresponding to the one or more selected advertisement categories.
2. The method of claim 1, further comprising:
preventing the presentation of any advertisement not corresponding to the one or more selected advertisement categories.
3. The method of claim 1, further comprising:
receiving and storing advertisements that do not correspond to the one or more selected advertisement categories.
4. The method of claim 1, further comprising:
receiving and storing only those advertisements that correspond to the one or more selected advertisement categories.
5. The method of claim 1, further comprising:
retrieving the advertisement from local storage.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method of administering to a host in need thereof an effective amount of methotrexate (MTX), said method comprising: administering to said host said effective amount of a MTX in conjunction with an amount of an MTX toxicity-reducing adjuvant effective to reduce toxicity of said MTX, wherein said MTX toxicity-reducing adjuvant is a 2,2\u2032-anhydropyrimidine of formula (I):
wherein
R2 is hydrogen;
R3 is hydroxyl or a halogen;
R4 is hydroxyl; and
R1 is a monoaralkylamino, a lower alkyl containing 1 to 20 carbons, or a substituted lower alkyl containing 1 to 20 carbons, wherein the substituent is selected from an alkoxy, an aryl substituted alkoxy, an imidate, an arylthio and an alkyl substituted arylthio;
or a pharmaceutically acceptable salt thereof.
2. The method according to claim 1, wherein the 2,2\u2032-anhydropyrimidine is described by one of the following structures:
3. The method according to claim 1, wherein R1 is methyl, ethyl, propyl, benzyl, CH3CH2OCH2\u2014 or CH3OCH2\u2014.
4. The method according to claim 3, wherein R1 is methyl.
5. The method according to claim 1, wherein said toxicity of said MTX is mucositis.
6. A pharmaceutical composition comprising an effective amount of both MTX and an MTX toxicity-reducing adjuvant in a pharmaceutically acceptable vehicle, wherein said MTX toxicity-reducing adjuvant is a 2,2\u2032-anhydropyrimidine of formula (I):
wherein
R2 is hydrogen;
R3 is hydroxyl or a halogen;
R4 is hydroxyl; and
R1 is a monoaralkylamino, a lower alkyl containing 1 to 20 carbons, or a substituted lower alkyl containing 1 to 20 carbons wherein the substituent is selected from an alkoxy, an aryl substituted alkoxy, an imidate, an arylthio and an alkyl substituted arylthio;
or a pharmaceutically acceptable salt thereof.
7. The pharmaceutical composition according to claim 6, wherein the 2,2\u2032-anhydropyrimidine is described by one of the following structures:
8. The pharmaceutical composition according to claim 6, wherein R1 is methyl, ethyl, propyl, benzyl, CH3CH2OCH2\u2014 or CH3OCH2\u2014.
9. The pharmaceutical composition according to claim 8, wherein R1 is methyl.
10. A method of administering to a host in need thereof an effective amount of methotrexate (MTX), said method comprising administering to said host a pharmaceutical composition consisting of:
said effective amount of MTX;
an effective amount of a MTX toxicity-reducing adjuvant that is a 2,2\u2032-anhydropyrimidine described by one of the following structures:
or a pharmaceutically acceptable salt thereof and
a pharmaceutically acceptable vehicle.
11. The method according to claim 10, wherein said 2,2\u2032-anhydropyrimidine is described by the structure:
12. A pharmaceutical composition consisting of:
an effective amount of MTX;
an effective amount of a MTX toxicity-reducing adjuvant that is a 2,2\u2032-anhydropyrimidine described by one of the following structures:
or a pharmaceutically acceptable salt thereof; and
a pharmaceutically acceptable vehicle.
13. The pharmaceutical composition according to claim 12, wherein said 2,2\u2032-anhydropyrimidine is described by the structure: